Pediatrik sarkom hastalarında profilaktik beta-glukan kullanımının nötropenik ateş sıklığı ve sağkalım üzerine etkisi
Abstract
Amaç: Kanser hastalarının bir kısmı, geleneksel kanser tedavilerini alırken, tamamlayıcı bitkisel tedavi kullanma eğilimindedir. Beta-glukanların bağışıklık sistemini uyarıcı etkisi yanında, kanser hücreleri üzerine doğrudan sitotoksik etkileri de vardır. Bu çalışmada, ekmek mayasından (Saccharomyces cerevisiae) elde edilen, 1,3-1,6 beta-glukan içeren besin takviyesi, sarkom tanılı hastalar tarafından kullanılmış ve retrospektif olarak beta-glukan kullanımının nötropenik ateş (NA) sıklığı ve sağkalım üzerine etkisinin değerlendirilmesi amaçlanmıştır.
Gereç ve Yöntem: 2014-2017 yılları arasında sarkom tanısı alan, beta-glukan kullanmış 27 hasta ve kontrol grubu olarak beta-glukan kullanmamış 31 hasta alındı. Hastaların klinik kayıtları geriye dönük olarak incelendi.
Bulgular: Beta-glukan grubunda NA geçiren hasta sayısı ve NA nedeniyle hastanede ortalama yatış süresi kontrol grubuna göre daha yüksekti ancak sonuçlar istatistiksel olarak anlamlı değildi. Genel sağkalım ve olaysız sağkalım açısından bakıldığında, beta-glukan ve kontrol grubunda 5. yılda genel sağkalım %83,3 ve %52,9, 5. yılda olaysız sağkalım %48,1 ve %71 idi.
Sonuç: Daha geniş hasta grubu ile prospektif olarak dizayn edilecek çalışmalar ile profilaktik beta-glukan kullanımının nötropenik ateş sıklığı ve sağ kalım oranları üzerine etkisi daha sağlıklı olarak değerlendirilebilir.
Supporting Institution
yok
Project Number
yok
References
- Referans1 McEachrane-Gross FP, Liebschutz JM, Berlowitz D. Use of selected complementary and alternative medicine (CAM) treatments in veterans with cancer or chronic pain: a cross-sectional survey BMC. Complement Altern Med. 2006;6:34.
- Referans2 Maheshwari G, Sowrirajan S, Joseph B. Extraction and Isolation of beta-Glucan from Grain Sources-A Review. J. Food Sci. 2017;82:1535–45.
- Referans3 Batbayar S, Lee DH, Kim HW. Immunomodulation of Fungal b-Glucan in Host Defense Signaling by Dectin-1. Biomol Ther. 2012;20:433–45.
- Referans4 Steimbach L, Borgmann AV, Gomar GG, Hoffmann LV, Rutckeviski R, Pereira de Andrade D, et al. Fungal beta-glucans as adjuvants for treating cancer patients - A systematic review of clinical trials. Clin Nutr. 2021;40:3104-13.
Effect of prophylactic beta-glucan use on the incidence of neutropenic fever and survival rates in pediatric patients with sarcoma
Abstract
Purpose: Some patients with cancer use herbal therapy as an adjunct while receiving conventional cancer treatments. Beta-glucans have direct cytotoxic effects on cancer cells as well as stimulatory effects on the immune system. In this study, a nutritional supplement containing 1,3-1,6 beta-glucan obtained from baker's yeast (Saccharomyces cerevisiae) was used by patients diagnosed with sarcoma, and this study aimed to retrospectively evaluate the effect of beta-glucan use on the incidence of neutropenic fever (NF) and survival rates.
Materials and Methods: Among the patients diagnosed with sarcoma between 2014 and 2017, 27 patients who used beta-glucan were included in the beta-glucan group, and 31 patients who did not use beta-glucan were included in the control group. The clinical records of patients were retrospectively analyzed.
Results: The number of patients who had NF and the mean length of hospital stay due to NF were higher in the beta-glucan group than those in the control group, but the results were not statistically significant. The overall survival rates at 5 years were 83.3% and 52.9% and event-free survival rates at 5 years were 48.1% and 71% in the beta-glucan and control groups, respectively.
Conclusion: The effect of prophylactic beta-glucan use on the incidence of NF and survival rates in pediatric patients with sarcoma should be evaluated more reliably in further prospective studies on a large patient group.
Project Number
yok
References
- Referans1 McEachrane-Gross FP, Liebschutz JM, Berlowitz D. Use of selected complementary and alternative medicine (CAM) treatments in veterans with cancer or chronic pain: a cross-sectional survey BMC. Complement Altern Med. 2006;6:34.
- Referans2 Maheshwari G, Sowrirajan S, Joseph B. Extraction and Isolation of beta-Glucan from Grain Sources-A Review. J. Food Sci. 2017;82:1535–45.
- Referans3 Batbayar S, Lee DH, Kim HW. Immunomodulation of Fungal b-Glucan in Host Defense Signaling by Dectin-1. Biomol Ther. 2012;20:433–45.
- Referans4 Steimbach L, Borgmann AV, Gomar GG, Hoffmann LV, Rutckeviski R, Pereira de Andrade D, et al. Fungal beta-glucans as adjuvants for treating cancer patients - A systematic review of clinical trials. Clin Nutr. 2021;40:3104-13.
Details
| Primary Language | English |
|---|---|
| Subjects | Clinical Sciences |
| Journal Section | Research |
| Authors | |
| Project Number | yok |
| Publication Date | June 30, 2022 |
| Acceptance Date | March 15, 2022 |
| Published in Issue | Year 2022 Volume: 47 Issue: 2 |
